Evaluation of Cerebral Vasoreactivity by SPECT and Transcranial Doppler Sonography using the Acetazolamide Test

Zusammenfassung

Bei 29 Patienten (3 Kontrollpersonen, 26 Patienten mit zerebrovaskulärer Erkrankung) wurde prospektiv die Hirn-SPECT mit ^99mTC-HMPAO und bei 20 Patienten (3 Kontrollpersonen, 17 Patienten mit ZVK) die transkranielle Dopplersonographie (TCD) vor und nach i. v. Gabe von Azetazolamid durchgeführt. Die Sensitivität der Hirn-SPECT erhöhte sich mit Azetazolamid von 62% auf 77%. Bei Patienten mit reversiblem neurologischem Defizit wurde eine Verbesserung von 50% auf 71 %, bei Patienten mit persistierendem Defizit von 75% auf 83% beobachtet. Die Ergebnisse der Hirn-SPECT und der TCD stimmten in der Beurteilung der zerebro-vaskulären Reservekapazität in 91% der Hemisphären überein. Die Korrelation zwischen den beiden Methoden war statistisch signifikant.

Summary

rCBF SPECT with ^99mTc-HMPAO was performed prospectively in 29 patients (3 controls and 26 stroke patients) as well as TCD studies in 20 patients (3 controls and 17 stroke patients) before and after 1 g i. v. acetazolamide. The sensitivity of rCBF SPECT increased from 62% to 77% after acetazolamide provocation in stroke patients. In patients with a reversible neurological deficit, the sensitivity under resting conditions was 50% which increased to 71%, while in cases with a permanent deficit it increased from 75% to 83%. In the evaluation of the cerebrovascular reserve capacity the results of rCBF SPECT and TCD coincided in 91 % of the hemispheres. The correlation was statistically significant.

Schlüsselwörter

Azetazolamid - zerebrovaskuläre Erkrankungen - SPECT - Ultraschall

Key words

Acetazolamide - cerebrovascular disorders - SPECT - ultrasonics

• REFERENCES

• 1 Ballinger JR, Reid RH, Gulenchyn KY. Radiochemical purity of [^99mTc]HM-PAO [Letter]. J Nucl Med 1988; 29: 572-3.
• 2 Büll U, Braun H, Ferbert A. et al. Combined SPECT imaging of regional cerebral blood flow (^99mTc-hexamethyl-propyleneamine-oxime, HMPAO) and blood volume (^99mTc-RBC) to assess regional cerebral perfusion reserve in patients with cerebrovascular disease. Nucl-Med 1988; 27: 51-6.
• 3 Burt RW, Witt RM, Cikrit DF, Reddy RV. Carotid artery disease: Evaluation with acetazolamide enhanced ^99mTc-HMPAO-SPECT. Radiology 1992; 182: 461-6.
• 4 Burt RW, Witt RM, Cikrit DC, Cartter J. Increased brain retention of ^99mTc HMPAO following acetazolamide administration. Clin Nucl Med 1991; 16: 568-71.
• 5 Dahl A, Lindegaard K-F, Russell D. et al. A comparison of transcranial Doppler and cerebral blood flow studies to assess cerebral vasoreactivity. Stroke 1992; 23: 15-9.
• 6 Devous Sr MD, Payne JK, Lowe JL. Dual-isotope brain SPECT imaging with ^99mTechnetium and ¹²³Iodine: Clinical validation using ¹³³Xenon SPECT. J Nucl Med 1992; 33: 1919-24.
• 7 Dingler W-H. HMPAO-SPECT mit Diamox Stimulation bei zerebrovaskulären Erkrankungen. Der Nuklearmediziner 1993; 16: 111-6.
• 8 Frackowiak RSJ. Pathophysiology of human cerebral ischaemia: Studies with positron tomography and 15-Oxygen. In: Sokoloff L. (ed). Brain imaging and brain function. New York: Raven Press; 1985: 139-61.
• 9 Holman BL, Devous MD. Functional brain SPECT: The emergence of a powerful clinical method. J Nucl Med 1992; 33: 1888-904.
• 10 Karnik R, Valentin A, Ammerer H-P. et al. Evaluation of vasomotor reactivity by transcranial Doppler and acetazolamide test before and after extracranial-intracranial bypass in patients with internal carotid artery occlusion. Stroke 1992; 23: 812-7.
• 11 Knapp WH, von Kummer R, Kübler W. et al. Imaging of cerebral blood flow to volume distribution using SPECT. J Nucl Med 1986; 27: 465-70.
• 12 Knop J, Thie A, Fuchs C. et al. ^99mTc-HMPAO-SPECT with acetazolamide challenge to detect hemodynamic compromise in occlusive cerebrovascular disease. Stroke 1992; 23: 1733-42.
• 13 Matsuda H, Higashi S, Kinuya K. et al. SPECT evaluation of brain perfusion reserve by the acetazolamide test using ^99mTc-HMPAO. Clin Nucl Med 1991; 16: 572-9.
• 14 Matsuda H, Tsuji S, Shuke N. et al. Non-invasive measurements of regional cerebral blood flow using ^99mTechnetium hexamethylpropylene amine oxime. Eur J Nucl Med 1993; 20: 391-401.
• 15 Pantano P, Di Piero V, Ricci M. et al. Motor stimulation response by ^99mTechnetium hexamethylpropylene amine oxime split-dose method and single photon emission tomography. Eur J Nucl Med 1992; 19: 939-45.
• 16 Piepgras A, Schmiedek P, Leinsinger G. et al. A simple test to assess cerebrovascular reserve capacity using transcranial Doppler sonography and acetazolamide. Stroke 1990; 21: 1306-11.
• 17 Powers WJ. Cerebral hemodynamics in ischemic cerebrovascular disease. Ann Neurol 1991; 29: 231-40.
• 18 Ring HA, George M, Costa DC, Ell PJ. The use of cerebral activation procedures with single photon emission tomography. Eur J Nucl Med 1991; 18: 133-41.
• 19 Ringelstein EB, Van Eyck S, Mertens I. Evaluation of cerebral vasomotor reactivity by various vasodilating stimuli: Comparison of C0₂ to acetazolamide. J Cereb Blood Flow Metab 1992; 12: 162-8.
• 20 Sorteberg W, Lindegaard K-F, Rootwelt K. et al. Effect of acetazolamide on cerebral artery blood velocity and regional cerebral blood flow in normal subjects. Acta Neuro-chir (Wien) 1989; 97: 139-45.
• 21 Tikofsky RS, Hellman RS. Brain single photon emission computed tomography: New activation and intervention studies. Sem Nucl Med 1991; 21: 40-57.
• 22 Toyama H, Takeshita G, Takeuchi A. et al. Cerebral hemodynamics in patients with chronic obstructive carotid disease by rCBF, rCBV and rCBV/rCBF ratio using SPECT. J Nucl Med 1990; 31: 55-60.
• 23 Volkert WA, Hoffman TJ, Seger RM. et al. ^99mTc-prophylene amine oxime (^99mTc-PnAO): potential brain radiopharmaceutical. Eur J Nucl Med 1984; 9: 511-6.
• 24 Yudd AP, Van Heertum RL, Masdeu JC. Interventions and functional brain imaging. Sem Nucl Med 1991; 21: 153-8.